ClinicalTrials.gg
CompletedNCT00958568Updated Apr 1, 2014Results posted

A Study in Relapse Prevention of Treatment-Resistant Depression

A Phase 3 interventional study of Olanzapine and Fluoxetine combination (OFC) and Fluoxetine in Treatment Resistant Depression, sponsored by Eli Lilly and Company. Completed at 66 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-04-01.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
892
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.

Enrollment
4th of 181
892 · median 38
Started
2009
with 3 others
Phase 3
18 of 204
3 open now
Registered
18th of 204
by date

Among the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 4th largest by enrollment of the 181 interventional ones that give a count, is one of 4 that started in 2009, is one of 18 in phase 3, and was the 18th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

43 of the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether olanzapine and fluoxetine combination (OFC) if used for a long time (47 weeks) makes patients suffering from Treatment Resistant Depression stable, determine if OFC is safe when used to treat patients with Treatment Resistant Depression for a long time (up to 47 weeks), to determine whether olanzapine and fluoxetine combination or fluoxetine alone is better to treat Treatment Resistant Depression when treated for a long time (up to 47 weeks) and to assess the quality of life during treatment.

Read the detailed description

This is a multicenter, randomized, double-blind, active comparator-controlled, parallel study of participants with Treatment Resistant Depression (TRD), comparing the efficacy and safety of olanzapine and fluoxetine Combination (OFC) versus fluoxetine in relapse prevention of stabilized participants with TRD. The study will consist of 4 phases: a screening phase; a 6- to 8-week open-label acute treatment phase; a 10- to 12-week open-label stabilization phase; and a 27- to 29-week double-blind relapse prevention treatment phase. Participants who demonstrate response to open-label OFC during the acute treatment phase will continue into the stabilization phase. Participants who remain stable while receiving open-label OFC during this phase will be randomized to receive either OFC or fluoxetine during the double-blind relapse prevention phase. Investigators and participants will be blinded to the precise duration of the stabilization period, the definition of remission, and the criteria for entry into the relapse prevention phase; this information is described in a supplement given to Ethical Review Boards (ERBs) and regulatory authorities.

03

Conditions studied

  • Treatment Resistant Depression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have single or recurrent unipolar Major Depressive Disorder (MDD), without psychotic features by , Fourth Edition-Text Revision (DSM-IV-TR) clinical assessment, confirmed by the structured clinician Interview for DSM-IV Axis 1 disorders (SCID-I).
  • If female and of , test negative for pregnancy and agree to abstain from sexual activity or use a medically accepted means of during the study. Use of any oral or injectable contraception must be initiated prior to receiving treatment.
  • Have 17-item Hamilton Depression (HAM-D) score greater than or equal to 18 at screening and the day treatment is due to be received for the first time.
  • Have treatment-resistant depression, as defined by having demonstrated failure to achieve satisfactory antidepressant response to adequate separate treatment courses of at least 2 different antidepressants within the current episode of MDD.

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis of Parkinson's disease or related disorders.
  • Have a current or lifetime diagnosis of any of the following according to criteria: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Psychotic Disorder Not Otherwise Specified, Bipolar Disorder I or II, Delirium of any type, Dementia of any type, Amnestic Disorder, any Substance-Induced Disorder, or any Psychotic Disorder due to a General Medical Condition.
  • Have current diagnosis of post-partum depression, MDD with atypical features, or MDD with a seasonal pattern as defined in the DSM-IV.
  • Have paranoid, schizoid, schizotypal, antisocial, and borderline personality disorders (Axis II) as a comorbid or primary diagnosis, based on DSM-IV criteria.
  • Have had psychotic symptoms within 1 month prior to Screening or demonstrate psychotic features at screening and on the day treatment is due to be assigned for the first time as determined by the investigator.
  • Have DSM-IV substance dependence/abuse or not willing to avoid use of the substance (not including dependence on nicotine or caffeine), as defined by the SCID-I, within the past 30 days.
  • Are actively suicidal in the judgment of the investigator.
  • Have had one or more seizures without a clear and resolved etiology.
  • Have leukopenia or history of leukopenia without a clear and resolved etiology, or known history of agranulocytosis during the participant's lifetime.
  • Have (ALT)/serum glutamic pyruvic transaminase (SGPT) values greater than or equal to 2 times the (ULN) of the performing laboratory or aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) values greater than or equal to 2 times the ULN or total values greater than or equal to 1.5 times the ULN at any time during screening.
  • Have acute, serious, or unstable medical conditions.
  • Have any illness such that death is anticipated within 1 year or intensive care unit hospitalization for the illness is anticipated within 6 months.
  • Have elevated prolactin levels at screening.
  • Have Bazett's interval (QTc) greater than 450 milliseconds (male) or greater than 470 milliseconds (female) at screening and when treatment is due to be received for the first time.
  • Have received electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS) treatment within the current episode; have a history of failure to adequate treatment courses of ECT or VNS; or will require ECT or VNS at any time during study participation.
  • If receiving psychotherapy, light therapy, or both, are anticipated to require changes in frequency/intensity of treatment regimen or to cease treatment regimen over the duration of the study. Participants who are not receiving any of these therapies upon study entry may not begin any of these therapies during screening, or during any treatment phases of the study.
  • Have received previous treatment with clozapine.
  • Have used a monoamine oxidase inhibitor (MAOI) within 14 days prior to screening or are expected to need MAOI treatment at any time during this study through 5 weeks after the participant discontinues from the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
892 participants (actual)

Study arms

  • Experimental
    Olanzapine and Fluoxetine combination (OFC)

    Drug: Olanzapine and Fluoxetine combination (OFC)

  • Active comparator
    Fluoxetine

    Drug: Fluoxetine

Interventions

  • DrugOlanzapine and Fluoxetine combination (OFC)

    Drug pages: Olanzapine · Fluoxetine

    Open label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks. Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks. Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks.

    Also known as: Symbyax, LY900000

  • 25 or 50 mg/day fixed dosing for 27 weeks

    Also known as: Prozac, LY1101440

06

What researchers measure

Primary outcomes

  1. Time to Relapse by Any Criteria

    Relapse defined as meeting any of these criteria: 50% increase in Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with a Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more; Hospitalized for depression or suicidality; Discontinued due to lack of efficacy/worsening of depression/suicidality. MADRS is a 10-item rating scale for depressive mood symptoms severity, items rated on 0-6 scale, with total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at discretion of investigator based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. Those who did not relapse were "censored" at their last observation.

    Time frame: Randomization (Week 20) to Week 47

Secondary outcomes

  1. Percentage of Participants Who Relapse by Any Criteria

    Relapse is defined as meeting any of the following criteria: 50% increase in Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more; Hospitalization for depression or suicidality; Discontinuation due to lack of efficacy/worsening of depression/suicidality. MADRS is a rating scale for severity of depressive mood symptoms with 10 items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at the discretion of the investigator and based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator.

    Time frame: Randomization (Week 20) to Week 47

  2. Percentage of Participants Who Relapse Based on Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score

    Relapse is defined as a 50% increase in the Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill).

    Time frame: Randomization (Week 20) to Week 47

  3. Percentage of Participants Who Relapse as Measured by Hospitalization for Depression or Suicidality

    Time frame: Randomization (Week 20) to Week 47

  4. Percentage of Participants Who Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality

    Lack of Efficacy/Worsening of depression was at the discretion of the investigator and was based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator.

    Time frame: Randomization (Week 20) to Week 47

  5. Time to Relapse Based on the Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score

    Relapse is defined as a 50% increase in the Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Those who did not relapse were "censored" at their last observation.

    Time frame: Randomization (Week 20) to Week 47

  6. Time to Relapse as Measured by Hospitalization for Depression or Suicidality

    Those who did not relapse were "censored" at their last observation.

    Time frame: Randomization (Week 20) to Week 47

  7. Time to Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality

    Lack of Efficacy/Worsening of depression was at the discretion of the investigator and was based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. Those who did not relapse were "censored" at their last observation.

    Time frame: Randomization (Week 20) to Week 47

  8. Percentage of Participants Responding to Treatment During Open-Label Acute Treatment Phase

    A 50% or greater improvement from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) and a Clinical Global Impressions-Severity (CGI-S) of Depression score ≤3 will be considered as response criteria met. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).

    Time frame: Week 0 to Week 8

  9. Percentage of Participants Maintaining Response at Any Point During Stabilization Treatment Phase

    A 50% or greater improvement from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) and a Clinical Global Impressions-Severity (CGI-S) of Depression score ≤3 will be considered as response criteria met. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).

    Time frame: Week 8 to Week 20

  10. Percentage of Participants Achieving Remission at Any Point During Stabilization Treatment Phase

    Remission is defined as the Montgomery-Asberg Depression Rating Scale (MADRS) score ≤8. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

    Time frame: Week 8 to Week 20

  11. Percentage of Participants Maintaining Remission

    Remission is defined as the Montgomery-Asberg Depression Rating Scale (MADRS) score ≤8. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

    Time frame: Randomization (Week 20) to Week 47

  12. Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Mixed-Effects Model Repeated Measures (MMRM) Analysis

    The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

    Time frame: Randomization (Week 20), Week 47

  13. Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Last Observation Carried Forward (LOCF) Analysis

    The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment and country.

    Time frame: Randomization (Week 20), up to Week 47

  14. Mean Change From Week 20 to Week 47 in Clinical Global Impressions - Severity (CGI-S) of Depression Using Mixed-Effects Model Repeated Measures (MMRM) Analysis

    CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

    Time frame: Randomization (Week 20), Week 47

  15. Resource Utilization - Average Number of Hours Worked for Pay Per Week at Week 47

    Time frame: Week 47

  16. Resource Utilization (Number of Psychiatric Visits, Number of Emergency Room or Equivalent Facility Visits for Psychiatric Illness)

    Resource utilization is defined as the average number of psychiatric visits and number of emergency room or equivalent facility visits for psychiatric illness.

    Time frame: Randomization (Week 20) to Week 47

  17. Change From Week 20 to Week 47 Endpoint in the Sheehan Disability Scale (SDS)

    The SDS is completed by the participant and is used to assess the effect of the participant's symptoms on their work or school (Item 1), social (Item 2), and family life and home responsibilities (Item 3). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Total scores is the sum of the 3 items and range from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment and country.

    Time frame: Randomization (Week 20), up to Week 47

  18. Percent of Participants With Treatment-Emergent Akathisia

    Barnes Akathisia Scale (BAS) rates observable, restless movements of drug-induced akathisia as well as the subjective awareness of restlessness and any distress associated with the akathisia. It consists of 4 items. 3 items (objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness) rated on a 4-point scale, with 0 being no akathisia and 3 being severe akathisia. Item 4 (global clinical assessment of Akathisia) is derived from the responses on Items 1-3 rated on a 6-point scale, with 0 being absence and 5 being extreme Akathisia. Treatment emergent akathisia is defined as a global clinical assessment score on BAS \<2 at baseline (Week 20) and a global clinical assessment score on BAS ≥2 post-baseline (Weeks 21-47).

    Time frame: Randomization (Week 20) to Week 47

  19. Percent of Participants With Treatment-Emergent Parkinsonism

    Simpson-Angus Scale is used to measure Parkinsonian-type symptoms in participants exposed to neuroleptics. The scale consists of 10 items, each rated on a 5-point scale, with 0 meaning complete absence of the condition and 4 meaning the presence of the condition in extreme form. The total score is obtained by adding the items and ranges from 0-40 with higher scores indicating worse conditions. Treatment emergent parkinsonism is defined as total score ≤3 of items 1 through 10 of the Simpson-Angus scale at baseline (Week 20) and a total score \>3 of items 1 through 10 post-baseline (Weeks 21-47).

    Time frame: Randomization (Week 20) to Week 47

  20. Percent of Participants With Treatment-Emergent Dyskinesia

    Abnormal Involuntary Movement Scale (AIMS) is a 12-item scale designed to record the occurrence of dyskinetic movements. Items 1 through 10 are rated on a 5-point scale, with 0 being no dyskinetic movements and 4 being severe dyskinetic movements. Items 11 and 12 are yes/no questions regarding the dental condition of the participants. Treatment emergent dyskinesia is defined as a score ≥3 on any one of the AIMS items 1-7 post-baseline (Weeks 21-47) or scores ≥2 on any two of the AIMS items 1-7 post-baseline (Weeks 21-47) among participants without either criteria at baseline (Week 20).

    Time frame: Randomization (Week 20) to Week 47

  21. Mean Change From Week 20 to Week 47 in Fasting Total Cholesterol

    Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

    Time frame: Randomization (Week 20), Week 47

  22. Percent of Participants With Treatment-Emergent High Fasting Total Cholesterol

    Borderline to High fasting total cholesterol: ≥200 milligrams/deciliter (mg/dL) and \<240 mg/dL at baseline and ≥240 mg/dL any time post baseline; Normal to Borderline fasting total cholesterol: \<200 mg/dL at baseline, ≥200 mg/dL and \<240 mg/dL any time post baseline; Normal to High fasting total cholesterol: \<200 mg/dL at baseline and ≥240 mg/dL any time post baseline.

    Time frame: Randomization (Week 20) to Week 47

  23. Mean Change From Week 20 to Week 47 in Fasting Low-Density Lipoprotein (LDL) Cholesterol

    Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

    Time frame: Randomization (Week 20), Week 47

  24. Percent of Participants With Treatment-Emergent High Fasting Low-Density Lipoprotein (LDL) Cholesterol

    Borderline to High fasting LDL cholesterol: ≥100 milligrams/deciliter (mg/dL) and \<160 mg/dL at baseline and ≥160 mg/dL any time post baseline; Normal to Borderline fasting LDL cholesterol: \<100 mg/dL at baseline, ≥100 mg/dL and \<160 mg/dL any time post baseline; Normal to High fasting LDL cholesterol: \<100 mg/dL at baseline and ≥160 mg/dL any time post baseline.

    Time frame: Randomization (Week 20) to Week 47

  25. Mean Change From Week 20 to Week 47 in Fasting High-Density Lipoprotein (HDL) Cholesterol

    Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

    Time frame: Randomization (Week 20), Week 47

  26. Percent of Participants With Treatment-Emergent Low Fasting High-Density Lipoprotein (HDL) Cholesterol

    Normal to Low fasting HDL cholesterol is ≥40 milligrams/deciliter (mg/dL) at baseline and \<40 mg/dL anytime post baseline.

    Time frame: Randomization (Week 20) to Week 47

  27. Percent of Participants With Treatment-Emergent Hepatic Events

    Participants with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<=3 times the upper limit of normal (ULN) at baseline, with ALT or AST \>=3 times the ULN post-baseline and total bilirubin \>=2 times ULN at the same time are considered having treatment-emergent hepatic events.

    Time frame: Randomization (Week 20) to Week 47

  28. Mean Change From Week 20 to Week 47 in Fasting Triglycerides

    Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

    Time frame: Randomization (Week 20), Week 47

  29. Percent of Participants With Treatment-Emergent High Fasting Triglycerides

    Borderline to High fasting triglycerides: ≥150 milligrams/deciliter (mg/dL) and \<200 mg/dL at baseline and ≥200 mg/dL any time post baseline; Normal to Borderline fasting triglycerides: \<150 mg/dL at baseline, ≥150 mg/dL and \<200 mg/dL any time post baseline; Normal to High fasting triglycerides: \<150 mg/dL at baseline and ≥200 mg/dL any time post baseline.

    Time frame: Randomization (Week 20) to Week 47

  30. Mean Change From Week 20 to Week 47 in Fasting Glucose

    Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

    Time frame: Randomization (Week 20), Week 47

  31. Percent of Participants With Treatment-Emergent High Fasting Glucose

    Impaired to High fasting glucose: ≥100 milligrams/deciliter (mg/dL) and \<126 mg/dL at baseline and ≥126 mg/dL any time post baseline; Normal to High glucose: \<100 mg/dL at baseline and ≥126 mg/dL any time post baseline; Normal to Impaired fasting glucose is \<100 mg/dL at baseline, ≥100 mg/dL and \<126 mg/dL any time post baseline; Normal/Impaired to High fasting glucose: \<126 mg/dL at baseline and ≥126 mg/dL any time post baseline.

    Time frame: Randomization (Week 20) to Week 47

  32. Mean Change From Week 20 to Week 47 in Weight

    Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

    Time frame: Randomization (Week 20), Week 47

  33. Percent of Participants With Week 20-to-Week 47 Endpoint Increase in Weight of at Least 7%

    Time frame: Week 20 to Week 47

  34. Percent of Participants With Suicide-Related Thoughts and Behaviors

    Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation: a "yes" answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Suicidal behavior: a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide.

    Time frame: Randomization (Week 20) to Week 47

  35. Mean Change in Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram

    Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

    Time frame: Randomization (Week 20), Week 47

  36. Percent of Participants With Treatment-Emergent Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram ≥500 Milliseconds (Msec)

    Data presented are the percent of participants whose baseline corrected (for rate) cardiac QT interval \<500 msec with post-baseline corrected (for rate) cardiac QT interval ≥500 msec.

    Time frame: Randomization (Week 20) to Week 47

  37. Percent of Participants With a 60 Milliseconds (Msec) Increase in Fridericia-Corrected (for Rate) Cardiac QT Interval (QTcF) on Electrocardiogram

    Time frame: Randomization (Week 20) to Week 47

Other outcomes

  1. Kaplan-Meier Estimate of Percentage of Subjects Not Relapsing at Week 27 (Day 189)

    Relapse is defined as meeting any of the following criteria (Relapse-any reason): 50% increase in MADRS score from randomization with concomitant CGI-S of Depression score increase to a score of 4 or more (MADRS score/CGI-S Depression Score); Hospitalization for depression or suicidality; Discontinuation due to lack of efficacy/worsening of depression/suicidality. MADRS is a rating scale for severity of depressive mood symptoms with 10 items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at the discretion of the investigator and based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator.

    Time frame: Randomization (Week 20) to Week 27

07

Results

Posted Apr 1, 2014

Participant flow

SPII (Wk 0-8, Acute Open-label)
Participant flow — SPII (Wk 0-8, Acute Open-label)
MilestoneOFC (SPII )OFC (SPIII)OFC (SPIV)Flu (SPIV)
Started892000
Completed655000
Not completed237000
Withdrew: Response criteria not met80000
Withdrew: Adverse event44000
Withdrew: Entry criteria not met34000
Withdrew: Withdrawal by subject39000
Withdrew: Lost to follow-up14000
Withdrew: Protocol violation13000
Withdrew: Physician decision4000
Withdrew: Sponsor decision8000
Withdrew: Unknown, not otherwise specified1000
SPIII (Wk 9-20,Open-label Stabilization)
Participant flow — SPIII (Wk 9-20,Open-label Stabilization)
MilestoneOFC (SPII )OFC (SPIII)OFC (SPIV)Flu (SPIV)
Started065500
Completed044400
Not completed021100
Withdrew: Stabilization criteria not met06200
Withdrew: Blinded randomization criteria not met03000
Withdrew: Adverse event02800
Withdrew: Withdrawal by subject04100
Withdrew: Protocol violation02400
Withdrew: Lost to follow-up0900
Withdrew: Entry criteria not met0600
Withdrew: Sponsor decision0500
Withdrew: Physician decision0400
Withdrew: Relapse criteria met0100
Withdrew: Unknown, not otherwise specified0100
SPIV (Wk 21-47, DB Relapse Prevention)
Participant flow — SPIV (Wk 21-47, DB Relapse Prevention)
MilestoneOFC (SPII )OFC (SPIII)OFC (SPIV)Flu (SPIV)
Started00221223
Completed00139117
Not completed0082106
Withdrew: Relapse criteria met002463
Withdrew: Adverse event001910
Withdrew: Withdrawal by subject001615
Withdrew: Protocol violation00115
Withdrew: Lost to follow-up0038
Withdrew: Sponsor decision0054
Withdrew: Entry criteria not met0021
Withdrew: Death0010
Withdrew: Physician decision0010

Outcome measures

PrimaryTime to Relapse by Any Criteria

Relapse defined as meeting any of these criteria: 50% increase in Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with a Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more; Hospitalized for depression or suicidality; Discontinued due to lack of efficacy/worsening of depression/suicidality. MADRS is a 10-item rating scale for depressive mood symptoms severity, items rated on 0-6 scale, with total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at discretion of investigator based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. Those who did not relapse were "censored" at their last observation.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Median · days
Time to Relapse by Any Criteria
daysOFC (SPIV)Flu (SPIV)
Time to Relapse by Any CriteriaNA ± 10.0NA ± 5.9
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Log Rank · p = <0.001 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryPercentage of Participants Who Relapse by Any Criteria

Relapse is defined as meeting any of the following criteria: 50% increase in Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more; Hospitalization for depression or suicidality; Discontinuation due to lack of efficacy/worsening of depression/suicidality. MADRS is a rating scale for severity of depressive mood symptoms with 10 items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at the discretion of the investigator and based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percentage of Participants Who Relapse by Any Criteria
percentage of participantsOFC (SPIV)Flu (SPIV)
Percentage of Participants Who Relapse by Any Criteria15.831.8
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Cochran-Mantel-Haenszel · p = <0.001 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)Relapse rates were analyzed using the Cochran-Mantel-Haenszel test adjusting for country.
SecondaryPercentage of Participants Who Relapse Based on Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score

Relapse is defined as a 50% increase in the Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill).

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percentage of Participants Who Relapse Based on Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score
percentage of participantsOFC (SPIV)Flu (SPIV)
Percentage of Participants Who Relapse Based on Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score14.028.3
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Cochran-Mantel-Haenszel · p = <0.001 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)Relapse rates were analyzed using the Cochran-Mantel-Haenszel test adjusting for country.
SecondaryPercentage of Participants Who Relapse as Measured by Hospitalization for Depression or Suicidality
Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percentage of Participants Who Relapse as Measured by Hospitalization for Depression or Suicidality
percentage of participantsOFC (SPIV)Flu (SPIV)
Percentage of Participants Who Relapse as Measured by Hospitalization for Depression or Suicidality1.81.3
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Cochran-Mantel-Haenszel · p = 0.713 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)Relapse rates were analyzed using the Cochran-Mantel-Haenszel test adjusting for country.
SecondaryPercentage of Participants Who Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality

Lack of Efficacy/Worsening of depression was at the discretion of the investigator and was based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percentage of Participants Who Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality
percentage of participantsOFC (SPIV)Flu (SPIV)
Percentage of Participants Who Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality10.928.3
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Cochran-Mantel-Haenszel · p = <0.001 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)Relapse rates were analyzed using the Cochran-Mantel-Haenszel test adjusting for country.
SecondaryTime to Relapse Based on the Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score

Relapse is defined as a 50% increase in the Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Those who did not relapse were "censored" at their last observation.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Median · days
Time to Relapse Based on the Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score
daysOFC (SPIV)Flu (SPIV)
Time to Relapse Based on the Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression ScoreNA ± 10.4NA ± 6.2
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Log Rank · p = <0.001 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryTime to Relapse as Measured by Hospitalization for Depression or Suicidality

Those who did not relapse were "censored" at their last observation.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Median · days
Time to Relapse as Measured by Hospitalization for Depression or Suicidality
daysOFC (SPIV)Flu (SPIV)
Time to Relapse as Measured by Hospitalization for Depression or SuicidalityNA ± 29.9NA ± 4.3
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Log Rank · p = 0.831 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryTime to Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality

Lack of Efficacy/Worsening of depression was at the discretion of the investigator and was based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. Those who did not relapse were "censored" at their last observation.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Median · days
Time to Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality
daysOFC (SPIV)Flu (SPIV)
Time to Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/SuicidalityNA ± 11.8NA ± 5.3
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Log Rank · p = <0.001 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryPercentage of Participants Responding to Treatment During Open-Label Acute Treatment Phase

A 50% or greater improvement from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) and a Clinical Global Impressions-Severity (CGI-S) of Depression score ≤3 will be considered as response criteria met. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).

Time frame:
Week 0 to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Responding to Treatment During Open-Label Acute Treatment Phase
percentage of participantsOFC (SPII-Wk 0-8, Acute Open-label)
Percentage of Participants Responding to Treatment During Open-Label Acute Treatment Phase78.0
SecondaryPercentage of Participants Maintaining Response at Any Point During Stabilization Treatment Phase

A 50% or greater improvement from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) and a Clinical Global Impressions-Severity (CGI-S) of Depression score ≤3 will be considered as response criteria met. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants).

Time frame:
Week 8 to Week 20
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Response at Any Point During Stabilization Treatment Phase
percentage of participantsOFC (SPIII)
Percentage of Participants Maintaining Response at Any Point During Stabilization Treatment Phase68.2
SecondaryPercentage of Participants Achieving Remission at Any Point During Stabilization Treatment Phase

Remission is defined as the Montgomery-Asberg Depression Rating Scale (MADRS) score ≤8. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

Time frame:
Week 8 to Week 20
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission at Any Point During Stabilization Treatment Phase
percentage of participantsOFC (SPIII)
Percentage of Participants Achieving Remission at Any Point During Stabilization Treatment Phase77.9
SecondaryPercentage of Participants Maintaining Remission

Remission is defined as the Montgomery-Asberg Depression Rating Scale (MADRS) score ≤8. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Remission
percentage of participantsOFC (SPIV)Flu (SPIV)
Percentage of Participants Maintaining Remission86.478.9
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Cochran-Mantel-Haenszel · p = 0.047 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)Remission rates were analyzed using the Cochran-Mantel-Haenszel test adjusting for country.
SecondaryMean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Mixed-Effects Model Repeated Measures (MMRM) Analysis

The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

Time frame:
Randomization (Week 20), Week 47
Reported as:
Least squares mean · units on a scale
Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Mixed-Effects Model Repeated Measures (MMRM) Analysis
units on a scaleOFC (SPIV)Flu (SPIV)
Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Mixed-Effects Model Repeated Measures (MMRM) Analysis2.06 ± 0.564.97 ± 0.61
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · t-test, 2 sided · p = <0.001 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.) · Ls mean difference: -2.91 · 95% CI -4.46 to -1.36The model adjusted for baseline (Week 20), treatment, country, visit, and treatment-by-visit interaction.
SecondaryMean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Last Observation Carried Forward (LOCF) Analysis

The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment and country.

Time frame:
Randomization (Week 20), up to Week 47
Reported as:
Least squares mean · units on a scale
Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Last Observation Carried Forward (LOCF) Analysis
units on a scaleOFC (SPIV)Flu (SPIV)
Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Last Observation Carried Forward (LOCF) Analysis3.03 ± 0.716.84 ± 0.73
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · t-test, 2 sided · p = <0.001 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.) · Ls mean difference: -3.82 · 95% CI -5.39 to -2.24The model adjusted for baseline (Week 20), treatment and country.
SecondaryMean Change From Week 20 to Week 47 in Clinical Global Impressions - Severity (CGI-S) of Depression Using Mixed-Effects Model Repeated Measures (MMRM) Analysis

CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

Time frame:
Randomization (Week 20), Week 47
Reported as:
Least squares mean · units on a scale
Mean Change From Week 20 to Week 47 in Clinical Global Impressions - Severity (CGI-S) of Depression Using Mixed-Effects Model Repeated Measures (MMRM) Analysis
units on a scaleOFC (SPIV)Flu (SPIV)
Mean Change From Week 20 to Week 47 in Clinical Global Impressions - Severity (CGI-S) of Depression Using Mixed-Effects Model Repeated Measures (MMRM) Analysis0.20 ± 0.080.54 ± 0.08
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · t-test, 2 sided · p = 0.002 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.) · Ls mean difference: -0.34 · 95% CI -0.55 to -0.12The model adjusted for baseline (Week 20), treatment, country, visit, and treatment-by-visit interaction.
SecondaryResource Utilization - Average Number of Hours Worked for Pay Per Week at Week 47
Time frame:
Week 47
Reported as:
Mean · hours
Resource Utilization - Average Number of Hours Worked for Pay Per Week at Week 47
hoursOFC (SPIV)Flu (SPIV)
Resource Utilization - Average Number of Hours Worked for Pay Per Week at Week 4737.49 ± 16.9537.76 ± 14.58
SecondaryResource Utilization (Number of Psychiatric Visits, Number of Emergency Room or Equivalent Facility Visits for Psychiatric Illness)

Resource utilization is defined as the average number of psychiatric visits and number of emergency room or equivalent facility visits for psychiatric illness.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Mean · visits per participant
Resource Utilization (Number of Psychiatric Visits, Number of Emergency Room or Equivalent Facility Visits for Psychiatric Illness)
visits per participantOFC (SPIV)Flu (SPIV)
Psychiatric visits (n=136, 113)0.65 ± 1.430.81 ± 1.52
Emergency room or equivalent facility visits0.00 ± 0.000.00 ± 0.00
SecondaryChange From Week 20 to Week 47 Endpoint in the Sheehan Disability Scale (SDS)

The SDS is completed by the participant and is used to assess the effect of the participant's symptoms on their work or school (Item 1), social (Item 2), and family life and home responsibilities (Item 3). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Total scores is the sum of the 3 items and range from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment and country.

Time frame:
Randomization (Week 20), up to Week 47
Reported as:
Least squares mean · units on a scale
Change From Week 20 to Week 47 Endpoint in the Sheehan Disability Scale (SDS)
units on a scaleOFC (SPIV)Flu (SPIV)
Change From Week 20 to Week 47 Endpoint in the Sheehan Disability Scale (SDS)1.30 ± 0.723.24 ± 0.73
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · t-test, 2 sided · p = 0.007 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.) · Ls mean difference: -1.94 · 95% CI -3.36 to -0.53The model adjusted for baseline (Week 20), treatment and country.
SecondaryPercent of Participants With Treatment-Emergent Akathisia

Barnes Akathisia Scale (BAS) rates observable, restless movements of drug-induced akathisia as well as the subjective awareness of restlessness and any distress associated with the akathisia. It consists of 4 items. 3 items (objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness) rated on a 4-point scale, with 0 being no akathisia and 3 being severe akathisia. Item 4 (global clinical assessment of Akathisia) is derived from the responses on Items 1-3 rated on a 6-point scale, with 0 being absence and 5 being extreme Akathisia. Treatment emergent akathisia is defined as a global clinical assessment score on BAS \<2 at baseline (Week 20) and a global clinical assessment score on BAS ≥2 post-baseline (Weeks 21-47).

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percent of Participants With Treatment-Emergent Akathisia
percentage of participantsOFC (SPIV)Flu (SPIV)
Percent of Participants With Treatment-Emergent Akathisia0.90.9
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 1.00 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryPercent of Participants With Treatment-Emergent Parkinsonism

Simpson-Angus Scale is used to measure Parkinsonian-type symptoms in participants exposed to neuroleptics. The scale consists of 10 items, each rated on a 5-point scale, with 0 meaning complete absence of the condition and 4 meaning the presence of the condition in extreme form. The total score is obtained by adding the items and ranges from 0-40 with higher scores indicating worse conditions. Treatment emergent parkinsonism is defined as total score ≤3 of items 1 through 10 of the Simpson-Angus scale at baseline (Week 20) and a total score \>3 of items 1 through 10 post-baseline (Weeks 21-47).

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percent of Participants With Treatment-Emergent Parkinsonism
percentage of participantsOFC (SPIV)Flu (SPIV)
Percent of Participants With Treatment-Emergent Parkinsonism1.40.0
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 0.248 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryPercent of Participants With Treatment-Emergent Dyskinesia

Abnormal Involuntary Movement Scale (AIMS) is a 12-item scale designed to record the occurrence of dyskinetic movements. Items 1 through 10 are rated on a 5-point scale, with 0 being no dyskinetic movements and 4 being severe dyskinetic movements. Items 11 and 12 are yes/no questions regarding the dental condition of the participants. Treatment emergent dyskinesia is defined as a score ≥3 on any one of the AIMS items 1-7 post-baseline (Weeks 21-47) or scores ≥2 on any two of the AIMS items 1-7 post-baseline (Weeks 21-47) among participants without either criteria at baseline (Week 20).

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percent of Participants With Treatment-Emergent Dyskinesia
percentage of participantsOFC (SPIV)Flu (SPIV)
Percent of Participants With Treatment-Emergent Dyskinesia0.50.0
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 1.00 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryMean Change From Week 20 to Week 47 in Fasting Total Cholesterol

Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

Time frame:
Randomization (Week 20), Week 47
Reported as:
Least squares mean · milligrams/deciliter (mg/dL)
Mean Change From Week 20 to Week 47 in Fasting Total Cholesterol
milligrams/deciliter (mg/dL)OFC (SPIV)Flu (SPIV)
Mean Change From Week 20 to Week 47 in Fasting Total Cholesterol-2.65 ± 3.24-1.74 ± 3.52
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · t-test, 2 sided · p = 0.839 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.) · Ls mean difference: -0.91 · 95% CI -9.71 to 7.89The model adjusted for baseline (Week 20), treatment, country, visit, and treatment-by-visit interaction.
SecondaryPercent of Participants With Treatment-Emergent High Fasting Total Cholesterol

Borderline to High fasting total cholesterol: ≥200 milligrams/deciliter (mg/dL) and \<240 mg/dL at baseline and ≥240 mg/dL any time post baseline; Normal to Borderline fasting total cholesterol: \<200 mg/dL at baseline, ≥200 mg/dL and \<240 mg/dL any time post baseline; Normal to High fasting total cholesterol: \<200 mg/dL at baseline and ≥240 mg/dL any time post baseline.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percent of Participants With Treatment-Emergent High Fasting Total Cholesterol
percentage of participantsOFC (SPIV)Flu (SPIV)
Borderline to High (n= 75, 83)28.020.5
Normal to Borderline (n=47, 59)17.016.9
Normal to High (n=47, 59)2.13.4
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 0.352 (P-value is for Borderline to High. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 1.00 (P-value is for Normal to Borderline. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 1.00 (P-value is for Normal to High. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryMean Change From Week 20 to Week 47 in Fasting Low-Density Lipoprotein (LDL) Cholesterol

Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

Time frame:
Randomization (Week 20), Week 47
Reported as:
Least squares mean · milligrams/deciliter (mg/dL)
Mean Change From Week 20 to Week 47 in Fasting Low-Density Lipoprotein (LDL) Cholesterol
milligrams/deciliter (mg/dL)OFC (SPIV)Flu (SPIV)
Mean Change From Week 20 to Week 47 in Fasting Low-Density Lipoprotein (LDL) Cholesterol-0.72 ± 2.960.85 ± 3.20
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · t-test, 2 sided · p = 0.703 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.) · Ls mean difference: -1.57 · 95% CI -9.69 to 6.54The model adjusted for baseline (Week 20), treatment, country, visit, and treatment-by-visit interaction.
SecondaryPercent of Participants With Treatment-Emergent High Fasting Low-Density Lipoprotein (LDL) Cholesterol

Borderline to High fasting LDL cholesterol: ≥100 milligrams/deciliter (mg/dL) and \<160 mg/dL at baseline and ≥160 mg/dL any time post baseline; Normal to Borderline fasting LDL cholesterol: \<100 mg/dL at baseline, ≥100 mg/dL and \<160 mg/dL any time post baseline; Normal to High fasting LDL cholesterol: \<100 mg/dL at baseline and ≥160 mg/dL any time post baseline.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percent of participants
Percent of Participants With Treatment-Emergent High Fasting Low-Density Lipoprotein (LDL) Cholesterol
percent of participantsOFC (SPIV)Flu (SPIV)
Borderline to High (n= 115, 134)17.410.4
Normal to Borderline (n=22, 26)22.730.8
Normal to High (n=22, 26)4.50.0
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 0.139 (P-value is for Borderline to High. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 0.746 (P-value is for Normal to Borderline. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 0.458 (P-value is for Normal to High. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryMean Change From Week 20 to Week 47 in Fasting High-Density Lipoprotein (HDL) Cholesterol

Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

Time frame:
Randomization (Week 20), Week 47
Reported as:
Least squares mean · milligrams/deciliter (mg/dL)
Mean Change From Week 20 to Week 47 in Fasting High-Density Lipoprotein (HDL) Cholesterol
milligrams/deciliter (mg/dL)OFC (SPIV)Flu (SPIV)
Mean Change From Week 20 to Week 47 in Fasting High-Density Lipoprotein (HDL) Cholesterol-1.71 ± 0.842.02 ± 0.92
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · t-test, 2 sided · p = 0.001 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.) · Ls mean difference: -3.73 · 95% CI -5.99 to -1.47The model adjusted for baseline (Week 20), treatment, country, visit, and treatment-by-visit interaction.
SecondaryPercent of Participants With Treatment-Emergent Low Fasting High-Density Lipoprotein (HDL) Cholesterol

Normal to Low fasting HDL cholesterol is ≥40 milligrams/deciliter (mg/dL) at baseline and \<40 mg/dL anytime post baseline.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percent of Participants With Treatment-Emergent Low Fasting High-Density Lipoprotein (HDL) Cholesterol
percentage of participantsOFC (SPIV)Flu (SPIV)
Percent of Participants With Treatment-Emergent Low Fasting High-Density Lipoprotein (HDL) Cholesterol39.225.5
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 0.004 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryPercent of Participants With Treatment-Emergent Hepatic Events

Participants with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<=3 times the upper limit of normal (ULN) at baseline, with ALT or AST \>=3 times the ULN post-baseline and total bilirubin \>=2 times ULN at the same time are considered having treatment-emergent hepatic events.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percent of Participants With Treatment-Emergent Hepatic Events
percentage of participantsOFC (SPIV)Flu (SPIV)
Percent of Participants With Treatment-Emergent Hepatic Events0.00.0
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 1.00 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryMean Change From Week 20 to Week 47 in Fasting Triglycerides

Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

Time frame:
Randomization (Week 20), Week 47
Reported as:
Least squares mean · milligrams/deciliter (mg/dL)
Mean Change From Week 20 to Week 47 in Fasting Triglycerides
milligrams/deciliter (mg/dL)OFC (SPIV)Flu (SPIV)
Mean Change From Week 20 to Week 47 in Fasting Triglycerides-8.24 ± 5.70-21.51 ± 6.20
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · t-test, 2 sided · p = 0.083 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.) · Ls mean difference: 13.27 · 95% CI -1.72 to 28.26The model adjusted for baseline (Week 20), treatment, country, visit, and treatment-by-visit interaction.
SecondaryPercent of Participants With Treatment-Emergent High Fasting Triglycerides

Borderline to High fasting triglycerides: ≥150 milligrams/deciliter (mg/dL) and \<200 mg/dL at baseline and ≥200 mg/dL any time post baseline; Normal to Borderline fasting triglycerides: \<150 mg/dL at baseline, ≥150 mg/dL and \<200 mg/dL any time post baseline; Normal to High fasting triglycerides: \<150 mg/dL at baseline and ≥200 mg/dL any time post baseline.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percent of Participants With Treatment-Emergent High Fasting Triglycerides
percentage of participantsOFC (SPIV)Flu (SPIV)
Borderline to High (n=47, 41)51.126.8
Normal to Borderline (n= 68, 74)22.16.8
Normal to High (n=68, 74)16.25.4
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 0.029 (P-value is for Borderline to High. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 0.014 (P-value is for Normal to Borderline. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 0.054 (P-value is for Normal to High. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryMean Change From Week 20 to Week 47 in Fasting Glucose

Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

Time frame:
Randomization (Week 20), Week 47
Reported as:
Least squares mean · milligrams/deciliter (mg/dL)
Mean Change From Week 20 to Week 47 in Fasting Glucose
milligrams/deciliter (mg/dL)OFC (SPIV)Flu (SPIV)
Mean Change From Week 20 to Week 47 in Fasting Glucose3.67 ± 1.36-2.22 ± 1.47
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · t-test, 2 sided · p = 0.002 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.) · Ls mean difference: 5.89 · 95% CI 2.22 to 9.56The model adjusted for baseline (Week 20), treatment, country, visit, and treatment-by-visit interaction.
SecondaryPercent of Participants With Treatment-Emergent High Fasting Glucose

Impaired to High fasting glucose: ≥100 milligrams/deciliter (mg/dL) and \<126 mg/dL at baseline and ≥126 mg/dL any time post baseline; Normal to High glucose: \<100 mg/dL at baseline and ≥126 mg/dL any time post baseline; Normal to Impaired fasting glucose is \<100 mg/dL at baseline, ≥100 mg/dL and \<126 mg/dL any time post baseline; Normal/Impaired to High fasting glucose: \<126 mg/dL at baseline and ≥126 mg/dL any time post baseline.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percent of Participants With Treatment-Emergent High Fasting Glucose
percentage of participantsOFC (SPIV)Flu (SPIV)
Impaired to High (n=98, 97)18.47.2
Normal to High (n=90, 96)4.45.2
Normal to Impaired (n=90, 96)35.628.1
Normal/Impaired to High (n= 188, 193)11.76.2
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 0.031 (P-value is for Impaired to High. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 1.00 (P-value is for Normal to High. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 0.344 (P-value is for Normal to Impaired. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 0.072 (P-value is for Normal/Impaired to High. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryMean Change From Week 20 to Week 47 in Weight

Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

Time frame:
Randomization (Week 20), Week 47
Reported as:
Least squares mean · kilograms (kg)
Mean Change From Week 20 to Week 47 in Weight
kilograms (kg)OFC (SPIV)Flu (SPIV)
Mean Change From Week 20 to Week 47 in Weight1.14 ± 0.33-2.78 ± 0.36
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · t-test, 2 sided · p = <0.001 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.) · Ls mean difference: 3.92 · 95% CI 2.96 to 4.88The model adjusted for baseline (Week 20), treatment, country, visit, and treatment-by-visit interaction.
SecondaryPercent of Participants With Week 20-to-Week 47 Endpoint Increase in Weight of at Least 7%
Time frame:
Week 20 to Week 47
Reported as:
Number · percentage of participants
Percent of Participants With Week 20-to-Week 47 Endpoint Increase in Weight of at Least 7%
percentage of participantsOFC (SPIV)Flu (SPIV)
Percent of Participants With Week 20-to-Week 47 Endpoint Increase in Weight of at Least 7%11.82.3
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = <0.001 (The threshold for statistical significance was 0.05.)
SecondaryPercent of Participants With Suicide-Related Thoughts and Behaviors

Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation: a "yes" answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Suicidal behavior: a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percent of Participants With Suicide-Related Thoughts and Behaviors
percentage of participantsOFC (SPIV)Flu (SPIV)
Suicidal Ideation4.16.3
Suicidal Behavior00
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · Fisher Exact · p = 0.392 (P-value is for suicidal ideation. The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.)
SecondaryMean Change in Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram

Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes baseline (Week 20), treatment, country, visit, and treatment by visit interaction.

Time frame:
Randomization (Week 20), Week 47
Reported as:
Least squares mean · milliseconds (msec)
Mean Change in Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram
milliseconds (msec)OFC (SPIV)Flu (SPIV)
Mean Change in Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram-3.12 ± 1.48-1.55 ± 1.60
Statistical analysis
  • OFC (SPIV) vs Flu (SPIV) · t-test, 2 sided · p = 0.421 (The test was run using an a priori 2-sided threshold for statistical significance of 0.05. No adjustments were made for multiple comparisons.) · Ls mean difference: -1.57 · 95% CI -5.42 to 2.27The model adjusted for baseline (Week 20), treatment, country, visit, and treatment-by-visit interaction.
SecondaryPercent of Participants With Treatment-Emergent Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram ≥500 Milliseconds (Msec)

Data presented are the percent of participants whose baseline corrected (for rate) cardiac QT interval \<500 msec with post-baseline corrected (for rate) cardiac QT interval ≥500 msec.

Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percent of Participants With Treatment-Emergent Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram ≥500 Milliseconds (Msec)
percentage of participantsOFC (SPIV)Flu (SPIV)
Percent of Participants With Treatment-Emergent Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram ≥500 Milliseconds (Msec)00
SecondaryPercent of Participants With a 60 Milliseconds (Msec) Increase in Fridericia-Corrected (for Rate) Cardiac QT Interval (QTcF) on Electrocardiogram
Time frame:
Randomization (Week 20) to Week 47
Reported as:
Number · percentage of participants
Percent of Participants With a 60 Milliseconds (Msec) Increase in Fridericia-Corrected (for Rate) Cardiac QT Interval (QTcF) on Electrocardiogram
percentage of participantsOFC (SPIV)Flu (SPIV)
Percent of Participants With a 60 Milliseconds (Msec) Increase in Fridericia-Corrected (for Rate) Cardiac QT Interval (QTcF) on Electrocardiogram00
Other pre-specifiedKaplan-Meier Estimate of Percentage of Subjects Not Relapsing at Week 27 (Day 189)

Relapse is defined as meeting any of the following criteria (Relapse-any reason): 50% increase in MADRS score from randomization with concomitant CGI-S of Depression score increase to a score of 4 or more (MADRS score/CGI-S Depression Score); Hospitalization for depression or suicidality; Discontinuation due to lack of efficacy/worsening of depression/suicidality. MADRS is a rating scale for severity of depressive mood symptoms with 10 items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at the discretion of the investigator and based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator.

Time frame:
Randomization (Week 20) to Week 27
Reported as:
Number · percentage of participants
Kaplan-Meier Estimate of Percentage of Subjects Not Relapsing at Week 27 (Day 189)
percentage of participantsOFC (SPIV)Flu (SPIV)
Relapse-any criteria83.6 (77.6 to 88.1)66.5 (59.6 to 72.5)
Relapse-MADRS score/CGI-S Depression Score85.3 (79.3 to 89.6)69.6 (62.7 to 75.5)
Relapse-Hospitalization for depression/suicidality97.7 (94.0 to 99.1)98.6 (95.6 to 99.5)
Relapse-Discontinued for lack efficacy/worsening87.4 (81.7 to 91.4)69.8 (63.0 to 75.6)

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OFC (SPII)—13/892 (1.5%)606/892 (67.9%)
OFC (SPIII)—9/655 (1.4%)348/655 (53.1%)
OFC (SPIV)—9/221 (4.1%)100/221 (45.2%)
Flu (SPIV)—7/223 (3.1%)105/223 (47.1%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventOFC (SPII)OFC (SPIII)OFC (SPIV)Flu (SPIV)
DepressionPsychiatric disorders1/8921/6553/2213/223
CholelithiasisHepatobiliary disorders0/8920/6551/2210/223
CellulitisInfections and infestations1/8921/6551/2210/223
Metastatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/8920/6551/2210/223
AggressionPsychiatric disorders0/8920/6551/2210/223
Homicidal ideationPsychiatric disorders0/8920/6551/2210/223
Suicidal ideationPsychiatric disorders1/8921/6551/2210/223
HaemoptysisRespiratory, thoracic and mediastinal disorders0/8920/6551/2210/223
Thrombophlebitis superficialVascular disorders0/8920/6551/2210/223
Chest painGeneral disorders0/8920/6550/2211/223
Most frequent other events
Showing 10 of 50
Most frequent other events
EventOFC (SPII)OFC (SPIII)OFC (SPIV)Flu (SPIV)
Weight increasedInvestigations151/89259/6558/2215/223
Dry mouthGastrointestinal disorders125/8928/6550/2211/223
Increased appetiteMetabolism and nutrition disorders123/89211/6553/2211/223
SomnolenceNervous system disorders76/89220/6551/2213/223
FatigueGeneral disorders68/89215/6552/2212/223
HeadacheNervous system disorders64/89239/65515/22113/223
InsomniaPsychiatric disorders20/89216/6558/22116/223
SedationNervous system disorders61/89217/6553/2210/223
NasopharyngitisInfections and infestations37/89223/6559/22112/223
DepressionPsychiatric disorders2/8924/6552/22112/223

Baseline characteristics

Age, Continuous
Age, Continuous(years)OFC (SPII-Wk 0-8, Acute Open-label)
Mean44.38 ± 11.98
Sex: Female, Male
Sex: Female, Male(Participants)OFC (SPII-Wk 0-8, Acute Open-label)
Female591
Male301
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OFC (SPII-Wk 0-8, Acute Open-label)
Hispanic or Latino167
Not Hispanic or Latino725
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OFC (SPII-Wk 0-8, Acute Open-label)
American Indian or Alaska Native27
Asian115
Native Hawaiian or Other Pacific Islander1
Black or African American101
White634
More than one race11
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(participants)OFC (SPII-Wk 0-8, Acute Open-label)
United States533
Mexico44
Puerto Rico20
Argentina53
Turkey28
Russian Federation66
South Africa40
India108
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms/square meter (kg/m²))OFC (SPII-Wk 0-8, Acute Open-label)
Mean29.12 ± 7.36
08

Study locations

66 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pasadena, California 91106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sherman Oaks, California 91403, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wildomar, California 92595, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cromwell, Connecticut 06416, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Washington, District of Columbia 20016, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30308, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marietta, Georgia 30060, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chicago, Illinois 60640, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oak Brook, Illinois 60523, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lafayette, Indiana 47905, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Florence, Kentucky 41042, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baltimore, Maryland 21285, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Glen Burnie, Maryland 21061, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Belmont, Massachusetts 02478, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boston, Massachusetts 02135, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bridgeton, Missouri 63044, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63141, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. Charles, Missouri 63301, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashua, New Hampshire 03060, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cherry Hill, New Jersey 08002, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brooklyn, New York 11235, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cedarhurst, New York 11516, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mount Kisco, New York 10549, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Staten Island, New York 10312, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beachwood, Ohio 44122, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Allentown, Pennsylvania 18103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Media, Pennsylvania 19063, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Philadelphia, Pennsylvania 19139, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Austin, Texas 78731, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Woodstock, Vermont 05091, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bellevue, Washington 98004, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seattle, Washington 98104, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spokane, Washington 99204, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brown Deer, Wisconsin 53223, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Middleton, Wisconsin 53562, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Allis, Wisconsin 53227, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Banfield, B1828CKR, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, C1122AAN, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Plata, 1900, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tucuman, 4000, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ahmedabad, 380013, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangalore, 560010, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chennai, 600003, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyderabaad, 500034, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ludhiana, 141001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mysore, 570004, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Raipur, 492001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Col. Florida, 01030, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 14330, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64640, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ponce, 00731-7779, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Khotkovo, 127025, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nizhniy Novgorod, 603155, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Petersburg, 192019, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Village Nikolskoe, 188357, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bellville, 7530, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Centurion, 0046, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    George, 6530, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kempton Park, 1619, South Africa
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Antalya, 07070, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Elazig, 23800, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gaziantep, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Istanbul, 34303, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    İstanbul, 34736, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mersin, 33079, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sisli, 80220, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2009
First posted
Aug 13, 2009
Start
Aug 2009
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Results first posted
Apr 1, 2014
Last update
Apr 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00958568
Responsible party
Sponsor
First posted
Aug 13, 2009
Start date
Aug 2009
Primary completion
Mar 2012
Completion
Mar 2012
Results posted
Apr 1, 2014
Last update
Apr 1, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olanzapine · Fluoxetine

Start the discussion